nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—melanoma—head and neck cancer	0.345	0.518	CtDrD
Vemurafenib—skin cancer—head and neck cancer	0.321	0.482	CtDrD
Vemurafenib—ABCC1—Vinblastine—head and neck cancer	0.047	0.199	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—head and neck cancer	0.0388	0.164	CbGbCtD
Vemurafenib—ABCG2—Fluorouracil—head and neck cancer	0.034	0.144	CbGbCtD
Vemurafenib—CYP2D6—Hydroxyurea—head and neck cancer	0.0302	0.128	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—head and neck cancer	0.0259	0.11	CbGbCtD
Vemurafenib—ALB—Fluorouracil—head and neck cancer	0.0234	0.099	CbGbCtD
Vemurafenib—CYP1A2—Fluorouracil—head and neck cancer	0.014	0.0592	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—head and neck cancer	0.0107	0.0452	CbGbCtD
Vemurafenib—CYP3A4—Vinblastine—head and neck cancer	0.0068	0.0288	CbGbCtD
Vemurafenib—CYP3A4—Docetaxel—head and neck cancer	0.0056	0.0237	CbGbCtD
Vemurafenib—Etoricoxib—PTGS2—head and neck cancer	0.00108	1	CrCbGaD
Vemurafenib—ORM1—saliva—head and neck cancer	0.000888	0.146	CbGeAlD
Vemurafenib—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.000683	0.0334	CcSEcCtD
Vemurafenib—Rash generalised—Docetaxel—head and neck cancer	0.000644	0.0315	CcSEcCtD
Vemurafenib—RAF1—hair follicle—head and neck cancer	0.00062	0.102	CbGeAlD
Vemurafenib—Neoplasm—Vinblastine—head and neck cancer	0.000523	0.0256	CcSEcCtD
Vemurafenib—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.000479	0.0235	CcSEcCtD
Vemurafenib—Neoplasm—Hydroxyurea—head and neck cancer	0.000477	0.0233	CcSEcCtD
Vemurafenib—Polyp—Docetaxel—head and neck cancer	0.00045	0.022	CcSEcCtD
Vemurafenib—RAF1—neck—head and neck cancer	0.000416	0.0685	CbGeAlD
Vemurafenib—Cyst—Docetaxel—head and neck cancer	0.00041	0.0201	CcSEcCtD
Vemurafenib—Hepatotoxicity—Docetaxel—head and neck cancer	0.000355	0.0174	CcSEcCtD
Vemurafenib—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000345	0.0169	CcSEcCtD
Vemurafenib—RAF1—parotid gland—head and neck cancer	0.000339	0.0558	CbGeAlD
Vemurafenib—Rigors—Docetaxel—head and neck cancer	0.000335	0.0164	CcSEcCtD
Vemurafenib—RAF1—saliva-secreting gland—head and neck cancer	0.000325	0.0534	CbGeAlD
Vemurafenib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000317	0.0155	CcSEcCtD
Vemurafenib—Photosensitivity—Fluorouracil—head and neck cancer	0.000314	0.0154	CcSEcCtD
Vemurafenib—ABCC1—hair follicle—head and neck cancer	0.00031	0.051	CbGeAlD
Vemurafenib—RAF1—connective tissue—head and neck cancer	0.000298	0.0491	CbGeAlD
Vemurafenib—BRAF—thyroid gland—head and neck cancer	0.000297	0.0489	CbGeAlD
Vemurafenib—Infestation—Hydroxyurea—head and neck cancer	0.000295	0.0144	CcSEcCtD
Vemurafenib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000295	0.0144	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000289	0.0141	CcSEcCtD
Vemurafenib—RAF1—epithelium—head and neck cancer	0.000283	0.0466	CbGeAlD
Vemurafenib—Alopecia—Vinblastine—head and neck cancer	0.000256	0.0126	CcSEcCtD
Vemurafenib—Dry skin—Fluorouracil—head and neck cancer	0.000252	0.0124	CcSEcCtD
Vemurafenib—RAF1—trachea—head and neck cancer	0.00025	0.0412	CbGeAlD
Vemurafenib—Neoplasm—Docetaxel—head and neck cancer	0.000248	0.0121	CcSEcCtD
Vemurafenib—Angiopathy—Hydroxyurea—head and neck cancer	0.00024	0.0118	CcSEcCtD
Vemurafenib—Chills—Hydroxyurea—head and neck cancer	0.000237	0.0116	CcSEcCtD
Vemurafenib—Eosinophilia—Fluorouracil—head and neck cancer	0.000236	0.0115	CcSEcCtD
Vemurafenib—Alopecia—Hydroxyurea—head and neck cancer	0.000234	0.0114	CcSEcCtD
Vemurafenib—Erythema—Hydroxyurea—head and neck cancer	0.00023	0.0113	CcSEcCtD
Vemurafenib—RAF1—lymphoid tissue—head and neck cancer	0.000218	0.0359	CbGeAlD
Vemurafenib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000217	0.0106	CcSEcCtD
Vemurafenib—Infestation NOS—Fluorouracil—head and neck cancer	0.000212	0.0104	CcSEcCtD
Vemurafenib—Infestation—Fluorouracil—head and neck cancer	0.000212	0.0104	CcSEcCtD
Vemurafenib—Atrial fibrillation—Docetaxel—head and neck cancer	0.00021	0.0103	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000208	0.0102	CcSEcCtD
Vemurafenib—Pain in extremity—Docetaxel—head and neck cancer	0.000199	0.00973	CcSEcCtD
Vemurafenib—RAF1—thyroid gland—head and neck cancer	0.000198	0.0326	CbGeAlD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000195	0.00954	CcSEcCtD
Vemurafenib—Infection—Hydroxyurea—head and neck cancer	0.000187	0.00915	CcSEcCtD
Vemurafenib—BRAF—lymph node—head and neck cancer	0.000185	0.0304	CbGeAlD
Vemurafenib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000184	0.00903	CcSEcCtD
Vemurafenib—Skin disorder—Hydroxyurea—head and neck cancer	0.000183	0.00894	CcSEcCtD
Vemurafenib—Dry skin—Docetaxel—head and neck cancer	0.000182	0.00892	CcSEcCtD
Vemurafenib—Decreased appetite—Vinblastine—head and neck cancer	0.000179	0.00877	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000179	0.00876	CcSEcCtD
Vemurafenib—Constipation—Vinblastine—head and neck cancer	0.000176	0.00863	CcSEcCtD
Vemurafenib—RAF1—head—head and neck cancer	0.000176	0.0289	CbGeAlD
Vemurafenib—ABCC1—parotid gland—head and neck cancer	0.000169	0.0279	CbGeAlD
Vemurafenib—Alopecia—Fluorouracil—head and neck cancer	0.000168	0.00824	CcSEcCtD
Vemurafenib—Erythema—Fluorouracil—head and neck cancer	0.000166	0.00812	CcSEcCtD
Vemurafenib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000163	0.008	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000162	0.00795	CcSEcCtD
Vemurafenib—Fatigue—Hydroxyurea—head and neck cancer	0.000162	0.00794	CcSEcCtD
Vemurafenib—Constipation—Hydroxyurea—head and neck cancer	0.000161	0.00787	CcSEcCtD
Vemurafenib—Weight decreased—Docetaxel—head and neck cancer	0.000155	0.00761	CcSEcCtD
Vemurafenib—Infestation—Docetaxel—head and neck cancer	0.000153	0.0075	CcSEcCtD
Vemurafenib—Infestation NOS—Docetaxel—head and neck cancer	0.000153	0.0075	CcSEcCtD
Vemurafenib—Hypersensitivity—Vinblastine—head and neck cancer	0.000152	0.00744	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000152	0.00743	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.00015	0.00735	CcSEcCtD
Vemurafenib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000149	0.00728	CcSEcCtD
Vemurafenib—Asthenia—Vinblastine—head and neck cancer	0.000148	0.00724	CcSEcCtD
Vemurafenib—Myalgia—Fluorouracil—head and neck cancer	0.000141	0.00691	CcSEcCtD
Vemurafenib—Diarrhoea—Vinblastine—head and neck cancer	0.000141	0.00691	CcSEcCtD
Vemurafenib—ABCG2—parotid gland—head and neck cancer	0.00014	0.0231	CbGeAlD
Vemurafenib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000139	0.00678	CcSEcCtD
Vemurafenib—Dizziness—Vinblastine—head and neck cancer	0.000136	0.00668	CcSEcCtD
Vemurafenib—Oedema peripheral—Docetaxel—head and neck cancer	0.000135	0.00663	CcSEcCtD
Vemurafenib—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000135	0.00663	CcSEcCtD
Vemurafenib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000135	0.00661	CcSEcCtD
Vemurafenib—Asthenia—Hydroxyurea—head and neck cancer	0.000135	0.0066	CcSEcCtD
Vemurafenib—Infection—Fluorouracil—head and neck cancer	0.000134	0.00658	CcSEcCtD
Vemurafenib—ABCG2—saliva-secreting gland—head and neck cancer	0.000134	0.0221	CbGeAlD
Vemurafenib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000133	0.0065	CcSEcCtD
Vemurafenib—Vomiting—Vinblastine—head and neck cancer	0.000131	0.00642	CcSEcCtD
Vemurafenib—Erythema multiforme—Docetaxel—head and neck cancer	0.00013	0.00636	CcSEcCtD
Vemurafenib—Headache—Vinblastine—head and neck cancer	0.000129	0.00632	CcSEcCtD
Vemurafenib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000129	0.0063	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—head and neck cancer	0.000128	0.00629	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—head and neck cancer	0.000128	0.00625	CcSEcCtD
Vemurafenib—Hypotension—Fluorouracil—head and neck cancer	0.000126	0.00619	CcSEcCtD
Vemurafenib—ABCC1—trachea—head and neck cancer	0.000125	0.0206	CbGeAlD
Vemurafenib—Angiopathy—Docetaxel—head and neck cancer	0.000125	0.00611	CcSEcCtD
Vemurafenib—Dizziness—Hydroxyurea—head and neck cancer	0.000124	0.00609	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000124	0.00607	CcSEcCtD
Vemurafenib—Chills—Docetaxel—head and neck cancer	0.000123	0.00604	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000123	0.00604	CcSEcCtD
Vemurafenib—RAF1—lymph node—head and neck cancer	0.000123	0.0202	CbGeAlD
Vemurafenib—Nausea—Vinblastine—head and neck cancer	0.000122	0.006	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—head and neck cancer	0.000122	0.00595	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—head and neck cancer	0.00012	0.00586	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—head and neck cancer	0.00012	0.00586	CcSEcCtD
Vemurafenib—Vomiting—Hydroxyurea—head and neck cancer	0.00012	0.00585	CcSEcCtD
Vemurafenib—Rash—Hydroxyurea—head and neck cancer	0.000119	0.0058	CcSEcCtD
Vemurafenib—Dermatitis—Hydroxyurea—head and neck cancer	0.000118	0.0058	CcSEcCtD
Vemurafenib—Headache—Hydroxyurea—head and neck cancer	0.000118	0.00577	CcSEcCtD
Vemurafenib—Decreased appetite—Fluorouracil—head and neck cancer	0.000118	0.00576	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—head and neck cancer	0.000117	0.00574	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000117	0.00572	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—head and neck cancer	0.000116	0.00567	CcSEcCtD
Vemurafenib—Nausea—Hydroxyurea—head and neck cancer	0.000112	0.00547	CcSEcCtD
Vemurafenib—Body temperature increased—Fluorouracil—head and neck cancer	0.000107	0.00524	CcSEcCtD
Vemurafenib—Cough—Docetaxel—head and neck cancer	0.000104	0.00511	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—head and neck cancer	0.000102	0.00499	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—head and neck cancer	0.000102	0.00499	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000101	0.00495	CcSEcCtD
Vemurafenib—Hypersensitivity—Fluorouracil—head and neck cancer	9.97e-05	0.00488	CcSEcCtD
Vemurafenib—ABCC1—thyroid gland—head and neck cancer	9.9e-05	0.0163	CbGeAlD
Vemurafenib—Anaphylactic shock—Docetaxel—head and neck cancer	9.77e-05	0.00478	CcSEcCtD
Vemurafenib—Infection—Docetaxel—head and neck cancer	9.71e-05	0.00475	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—head and neck cancer	9.58e-05	0.00469	CcSEcCtD
Vemurafenib—Pruritus—Fluorouracil—head and neck cancer	9.58e-05	0.00469	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—head and neck cancer	9.49e-05	0.00465	CcSEcCtD
Vemurafenib—Diarrhoea—Fluorouracil—head and neck cancer	9.26e-05	0.00453	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—head and neck cancer	9.13e-05	0.00447	CcSEcCtD
Vemurafenib—Dizziness—Fluorouracil—head and neck cancer	8.95e-05	0.00438	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	8.9e-05	0.00436	CcSEcCtD
Vemurafenib—Vomiting—Fluorouracil—head and neck cancer	8.61e-05	0.00421	CcSEcCtD
Vemurafenib—Rash—Fluorouracil—head and neck cancer	8.53e-05	0.00418	CcSEcCtD
Vemurafenib—Dermatitis—Fluorouracil—head and neck cancer	8.53e-05	0.00417	CcSEcCtD
Vemurafenib—ORM1—lymph node—head and neck cancer	8.49e-05	0.014	CbGeAlD
Vemurafenib—Decreased appetite—Docetaxel—head and neck cancer	8.49e-05	0.00416	CcSEcCtD
Vemurafenib—Headache—Fluorouracil—head and neck cancer	8.48e-05	0.00415	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—head and neck cancer	8.43e-05	0.00413	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—head and neck cancer	8.42e-05	0.00412	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—head and neck cancer	8.35e-05	0.00409	CcSEcCtD
Vemurafenib—ABCG2—thyroid gland—head and neck cancer	8.19e-05	0.0135	CbGeAlD
Vemurafenib—Nausea—Fluorouracil—head and neck cancer	8.04e-05	0.00394	CcSEcCtD
Vemurafenib—CYP1A2—thyroid gland—head and neck cancer	7.88e-05	0.013	CbGeAlD
Vemurafenib—Body temperature increased—Docetaxel—head and neck cancer	7.72e-05	0.00378	CcSEcCtD
Vemurafenib—ALB—lymph node—head and neck cancer	7.45e-05	0.0123	CbGeAlD
Vemurafenib—Hypersensitivity—Docetaxel—head and neck cancer	7.2e-05	0.00352	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—head and neck cancer	7.01e-05	0.00343	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—head and neck cancer	6.91e-05	0.00338	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—head and neck cancer	6.68e-05	0.00327	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—head and neck cancer	6.46e-05	0.00316	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—head and neck cancer	6.21e-05	0.00304	CcSEcCtD
Vemurafenib—Rash—Docetaxel—head and neck cancer	6.16e-05	0.00302	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—head and neck cancer	6.15e-05	0.00301	CcSEcCtD
Vemurafenib—ABCC1—lymph node—head and neck cancer	6.15e-05	0.0101	CbGeAlD
Vemurafenib—Headache—Docetaxel—head and neck cancer	6.12e-05	0.003	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—head and neck cancer	5.8e-05	0.00284	CcSEcCtD
Vemurafenib—ABCG2—lymph node—head and neck cancer	5.09e-05	0.00838	CbGeAlD
Vemurafenib—CYP2D6—head—head and neck cancer	4.98e-05	0.0082	CbGeAlD
Vemurafenib—ABCC1—Metabolism—DPYD—head and neck cancer	2.11e-05	0.000299	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—PIK3CA—head and neck cancer	2.11e-05	0.000298	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—AKT1—head and neck cancer	2.11e-05	0.000298	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—AKT1—head and neck cancer	2.1e-05	0.000296	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—head and neck cancer	2.09e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—AKT1—head and neck cancer	2.09e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—head and neck cancer	2.09e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—head and neck cancer	2.08e-05	0.000294	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—AKT1—head and neck cancer	2.08e-05	0.000293	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—AKT1—head and neck cancer	2.07e-05	0.000292	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—head and neck cancer	2.05e-05	0.00029	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	2.04e-05	0.000288	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	2.04e-05	0.000288	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—AKT1—head and neck cancer	2.03e-05	0.000286	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	2.01e-05	0.000284	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—YAP1—head and neck cancer	2e-05	0.000283	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—MAPK3—head and neck cancer	2e-05	0.000282	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—head and neck cancer	2e-05	0.000282	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.99e-05	0.000282	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GRP—head and neck cancer	1.97e-05	0.000278	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—MAPK3—head and neck cancer	1.96e-05	0.000278	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—head and neck cancer	1.95e-05	0.000276	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—AKT1—head and neck cancer	1.94e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—AKT1—head and neck cancer	1.94e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	1.94e-05	0.000275	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	1.93e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—AKT1—head and neck cancer	1.93e-05	0.000272	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—AKT1—head and neck cancer	1.91e-05	0.000271	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT6—head and neck cancer	1.91e-05	0.00027	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—AKT1—head and neck cancer	1.91e-05	0.00027	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	1.91e-05	0.00027	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—MAPK1—head and neck cancer	1.9e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—AKT1—head and neck cancer	1.9e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—MAPK1—head and neck cancer	1.9e-05	0.000269	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	1.88e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—head and neck cancer	1.88e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—MAPK1—head and neck cancer	1.87e-05	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—head and neck cancer	1.87e-05	0.000264	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—DPYD—head and neck cancer	1.86e-05	0.000263	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CASP8—head and neck cancer	1.84e-05	0.000261	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—AKT1—head and neck cancer	1.84e-05	0.00026	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	1.83e-05	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MAPK3—head and neck cancer	1.78e-05	0.000251	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—YAP1—head and neck cancer	1.76e-05	0.000249	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CDH1—head and neck cancer	1.75e-05	0.000247	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—head and neck cancer	1.72e-05	0.000243	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	1.71e-05	0.000242	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UROD—head and neck cancer	1.7e-05	0.00024	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—YAP1—head and neck cancer	1.69e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MAPK1—head and neck cancer	1.69e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—head and neck cancer	1.69e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—PIK3CA—head and neck cancer	1.65e-05	0.000233	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	1.63e-05	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—PIK3CA—head and neck cancer	1.62e-05	0.000229	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	1.61e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—BCL2—head and neck cancer	1.58e-05	0.000224	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOTCH1—head and neck cancer	1.57e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—head and neck cancer	1.55e-05	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—head and neck cancer	1.53e-05	0.000216	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—head and neck cancer	1.52e-05	0.000216	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.51e-05	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—head and neck cancer	1.5e-05	0.000212	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.39e-05	0.000196	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.37e-05	0.000194	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	1.37e-05	0.000194	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—head and neck cancer	1.36e-05	0.000192	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—head and neck cancer	1.34e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—head and neck cancer	1.33e-05	0.000188	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—AKT1—head and neck cancer	1.32e-05	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—head and neck cancer	1.31e-05	0.000186	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.31e-05	0.000186	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2L1—head and neck cancer	1.31e-05	0.000186	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PTEN—head and neck cancer	1.31e-05	0.000185	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NAT2—head and neck cancer	1.31e-05	0.000185	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	1.3e-05	0.000184	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MAPK3—head and neck cancer	1.27e-05	0.000179	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PTEN—head and neck cancer	1.26e-05	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MAPK3—head and neck cancer	1.24e-05	0.000176	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	1.24e-05	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MAPK1—head and neck cancer	1.21e-05	0.000171	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—head and neck cancer	1.21e-05	0.00017	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TYMS—head and neck cancer	1.2e-05	0.00017	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTM1—head and neck cancer	1.19e-05	0.000168	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MAPK1—head and neck cancer	1.18e-05	0.000167	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—head and neck cancer	1.17e-05	0.000165	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DPYD—head and neck cancer	1.15e-05	0.000162	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—head and neck cancer	1.14e-05	0.000161	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP1A1—head and neck cancer	1.13e-05	0.000159	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MAPK3—head and neck cancer	1.12e-05	0.000158	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOTCH1—head and neck cancer	1.1e-05	0.000156	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—YAP1—head and neck cancer	1.09e-05	0.000154	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOTCH1—head and neck cancer	1.09e-05	0.000154	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NAT2—head and neck cancer	1.08e-05	0.000153	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOTCH1—head and neck cancer	1.08e-05	0.000153	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CASP8—head and neck cancer	1.07e-05	0.000152	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	1.07e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MAPK1—head and neck cancer	1.06e-05	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—head and neck cancer	1.06e-05	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDH1—head and neck cancer	1.06e-05	0.00015	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TYMS—head and neck cancer	1.06e-05	0.00015	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTM1—head and neck cancer	1.05e-05	0.000148	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PIK3CA—head and neck cancer	1.03e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—head and neck cancer	1.02e-05	0.000145	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTEN—head and neck cancer	1.02e-05	0.000144	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—head and neck cancer	1e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—head and neck cancer	9.93e-06	0.00014	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP1A1—head and neck cancer	9.92e-06	0.00014	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	9.71e-06	0.000137	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—head and neck cancer	9.68e-06	0.000137	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	9.61e-06	0.000136	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—head and neck cancer	9.5e-06	0.000134	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DPYD—head and neck cancer	9.47e-06	0.000134	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.26e-06	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—PIK3CA—head and neck cancer	9.24e-06	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2—head and neck cancer	9.21e-06	0.00013	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NAT2—head and neck cancer	9.15e-06	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—head and neck cancer	9.1e-06	0.000129	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—YAP1—head and neck cancer	8.98e-06	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—head and neck cancer	8.87e-06	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—PIK3CA—head and neck cancer	8.87e-06	0.000125	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	8.75e-06	0.000124	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MAPK3—head and neck cancer	8.7e-06	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—head and neck cancer	8.55e-06	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—head and neck cancer	8.55e-06	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—head and neck cancer	8.38e-06	0.000119	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—head and neck cancer	8.32e-06	0.000118	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MAPK1—head and neck cancer	8.28e-06	0.000117	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—head and neck cancer	8.28e-06	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—head and neck cancer	8.21e-06	0.000116	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.17e-06	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—head and neck cancer	8.11e-06	0.000115	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—head and neck cancer	8.08e-06	0.000114	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DPYD—head and neck cancer	8.02e-06	0.000113	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—head and neck cancer	8.01e-06	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—head and neck cancer	7.63e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—head and neck cancer	7.62e-06	0.000108	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—YAP1—head and neck cancer	7.61e-06	0.000108	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—head and neck cancer	7.58e-06	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—head and neck cancer	7.55e-06	0.000107	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—head and neck cancer	7.39e-06	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—head and neck cancer	7.25e-06	0.000103	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—head and neck cancer	7.18e-06	0.000102	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK3—head and neck cancer	7.13e-06	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—head and neck cancer	7.13e-06	0.000101	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.13e-06	0.000101	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—head and neck cancer	7.07e-06	0.0001	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NAT2—head and neck cancer	7.06e-06	9.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—head and neck cancer	7.04e-06	9.96e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—head and neck cancer	6.98e-06	9.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—head and neck cancer	6.82e-06	9.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK1—head and neck cancer	6.79e-06	9.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—head and neck cancer	6.79e-06	9.6e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—head and neck cancer	6.7e-06	9.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—head and neck cancer	6.69e-06	9.46e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—head and neck cancer	6.64e-06	9.4e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—head and neck cancer	6.53e-06	9.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—head and neck cancer	6.52e-06	9.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—head and neck cancer	6.46e-06	9.13e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—head and neck cancer	6.44e-06	9.11e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—head and neck cancer	6.38e-06	9.02e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK1—head and neck cancer	6.37e-06	9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—head and neck cancer	6.3e-06	8.91e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—head and neck cancer	6.24e-06	8.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK1—head and neck cancer	6.2e-06	8.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—head and neck cancer	6.2e-06	8.77e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DPYD—head and neck cancer	6.19e-06	8.75e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—head and neck cancer	6.18e-06	8.75e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A1—head and neck cancer	6.12e-06	8.66e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—head and neck cancer	6.09e-06	8.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—head and neck cancer	6.02e-06	8.51e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—head and neck cancer	5.97e-06	8.44e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—head and neck cancer	5.9e-06	8.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—head and neck cancer	5.89e-06	8.33e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—YAP1—head and neck cancer	5.87e-06	8.31e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—head and neck cancer	5.87e-06	8.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—head and neck cancer	5.85e-06	8.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK1—head and neck cancer	5.8e-06	8.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—head and neck cancer	5.79e-06	8.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK1—head and neck cancer	5.73e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—head and neck cancer	5.73e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	5.72e-06	8.09e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK1—head and neck cancer	5.68e-06	8.03e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—head and neck cancer	5.68e-06	8.03e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—head and neck cancer	5.52e-06	7.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—head and neck cancer	5.45e-06	7.71e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—head and neck cancer	5.39e-06	7.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—head and neck cancer	5.38e-06	7.61e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—head and neck cancer	5.34e-06	7.56e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—head and neck cancer	5.33e-06	7.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—head and neck cancer	5.24e-06	7.41e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—head and neck cancer	5.15e-06	7.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—head and neck cancer	5.11e-06	7.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—head and neck cancer	5.11e-06	7.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—head and neck cancer	5.11e-06	7.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.05e-06	7.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—head and neck cancer	5.03e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.03e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	4.99e-06	7.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—head and neck cancer	4.98e-06	7.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—head and neck cancer	4.97e-06	7.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—head and neck cancer	4.93e-06	6.98e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—head and neck cancer	4.93e-06	6.97e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—head and neck cancer	4.87e-06	6.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—head and neck cancer	4.81e-06	6.81e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—head and neck cancer	4.65e-06	6.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—head and neck cancer	4.6e-06	6.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—head and neck cancer	4.57e-06	6.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—head and neck cancer	4.56e-06	6.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—head and neck cancer	4.52e-06	6.39e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—head and neck cancer	4.51e-06	6.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—head and neck cancer	4.46e-06	6.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—head and neck cancer	4.41e-06	6.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—head and neck cancer	4.4e-06	6.22e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—head and neck cancer	4.33e-06	6.12e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	4.28e-06	6.06e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—head and neck cancer	4.21e-06	5.96e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—head and neck cancer	4.13e-06	5.83e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—head and neck cancer	4.11e-06	5.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—head and neck cancer	4.06e-06	5.74e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—head and neck cancer	4.02e-06	5.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK1—head and neck cancer	4.01e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—head and neck cancer	4.01e-06	5.67e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—head and neck cancer	3.64e-06	5.15e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—head and neck cancer	3.63e-06	5.13e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—head and neck cancer	3.53e-06	4.99e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.52e-06	4.98e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.49e-06	4.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—head and neck cancer	3.48e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—head and neck cancer	3.37e-06	4.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—head and neck cancer	3.37e-06	4.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—head and neck cancer	3.34e-06	4.72e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	3.3e-06	4.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—head and neck cancer	3.22e-06	4.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—head and neck cancer	3.17e-06	4.49e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.01e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—head and neck cancer	2.97e-06	4.19e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—head and neck cancer	2.84e-06	4.02e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—head and neck cancer	2.62e-06	3.71e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—head and neck cancer	2.55e-06	3.6e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—head and neck cancer	2.24e-06	3.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—head and neck cancer	2.22e-06	3.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.97e-06	2.78e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.85e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—head and neck cancer	1.83e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—head and neck cancer	1.71e-06	2.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	1.57e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—head and neck cancer	1.51e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—head and neck cancer	1.28e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.21e-06	1.71e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—head and neck cancer	9.88e-07	1.4e-05	CbGpPWpGaD
